Overview

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Status:
Terminated

Trial end date:
2004-10-05

Target enrollment:

Participant gender:

Summary

The study compares valdecoxib 40 mg once daily vs. rofecoxib 50 mg one daily in treating the signs and symptoms of acute first- or second-degree ankle sprain. The study also evaluated the disability status, tolerability and safety of these treatments.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Rofecoxib
Valdecoxib